GSK, Amira Team Up In $425 Million Asthma Collaboration
Deal gives GSK rights to Amira’s FLAP inhibitors for the treatment of respiratory and cardiovascular disease.
Deal gives GSK rights to Amira’s FLAP inhibitors for the treatment of respiratory and cardiovascular disease.